S&P 500
(1.30%) 5 129.96 points
Dow Jones
(1.27%) 38 712 points
Nasdaq
(2.02%) 16 162 points
Oil
(-0.82%) $78.30
Gas
(5.31%) $2.14
Gold
(0.06%) $2 311.00
Silver
(-0.39%) $26.73
Platinum
(0.39%) $966.40
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.23%) $10.86
USD/GBP
(-0.10%) $0.797
USD/RUB
(0.37%) $91.47

Actualizaciones en tiempo real para Viking Therapeutics Inc [VKTX]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
BUY
57.14%
return 7.81%
SELL
39.58%
return -81.32%
Última actualización3 may 2024 @ 14:03

1.81% $ 77.14

VENDER 149 min ago

@ $76.59

Emitido: 3 may 2024 @ 11:33


Retorno: 0.72%


Señal anterior: may 2 - 13:44


Señal anterior: Comprar


Retorno: 1.55 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 14:03):

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders...

Stats
Volumen de hoy 2.53M
Volumen promedio 6.51M
Capitalización de mercado 8.51B
EPS $-0.250 ( 2024-04-24 )
Próxima fecha de ganancias ( $-0.250 ) 2024-07-24
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -83.84
ATR14 $4.80 (6.22%)
Insider Trading
Date Person Action Amount type
2024-05-01 Mancini Marianna Buy 51 000 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Sell 23 746 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Sell 26 142 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Buy 35 426 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Buy 90 000 Common Stock, par value $0.00001 per share
INSIDER POWER
1.01
Last 100 transactions
Buy: 2 844 296 | Sell: 2 903 733

Volumen Correlación

Largo: 0.81 (strong)
Corto: 0.82 (strong)
Signal:(57) Same movement expected

Viking Therapeutics Inc Correlación

10 Correlaciones Más Positivas
CFFE0.97
ARIZ0.966
EMLD0.96
ARTEU0.96
AIB0.958
GENQ0.956
FTII0.956
ABST0.955
GDST0.955
KIN0.954
10 Correlaciones Más Negativas
SMFL-0.968
CYAN-0.963
MYSZ-0.96
PIII-0.958
CREG-0.955
BCAB-0.95
PYR-0.95
SPCX-0.949
KTTA-0.948
VFF-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Viking Therapeutics Inc Correlación - Moneda/Commodity

The country flag 0.63
( weak )
The country flag 0.74
( moderate )
The country flag 0.00
( neutral )
The country flag 0.49
( neutral )
The country flag 0.47
( neutral )
The country flag -0.48
( neutral )

Viking Therapeutics Inc Finanzas

Annual 2023
Ingresos: $0
Beneficio Bruto: $-292 000 (0.00 %)
EPS: $-0.910
FY 2023
Ingresos: $0
Beneficio Bruto: $-292 000 (0.00 %)
EPS: $-0.910
FY 2022
Ingresos: $0
Beneficio Bruto: $-291 000 (0.00 %)
EPS: $-0.880
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-0.757

Financial Reports:

No articles found.

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico